Every intervention Outliyr has scored for neuroplasticity, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for neuroplasticity; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
36 of 90 evaluated interventions score 3.0+ out of 10 for neuroplasticity · 8 comparisons
Ostinelli et al. 2025 supports the core mechanism. Neurofeedback directly trains learned self-regulation of brain activity. Sitaram 2017 describes closed-loop brain training as a neuroplasticity tool, and Van Doren 2019 supports durability…
Chronic stroke, TBI, and cognitive-aging studies repeatedly invoke perfusion and neuroplasticity signals. Efrati 2013 reports neurological improvement with brain perfusion changes in chronic post-stroke patients. Score above neutral with the caveat that…
The existing rationale points to this narrower claim: Aerobic exercise supports BDNF and vascular mechanisms that help neuroplasticity. Zone 2 deserves a solid score as a base intervention, but learning. That does…
Willis 2025 anchors the most relevant signal. Lion's Mane fits neuroplasticity when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or gut-immune signaling over weeks. The score stays bounded…
The neuroplasticity score rests on Dolotov et al. 2006, which found BDNF and TrkB upregulation in rat hippocampus after intranasal Semax, not on direct human neuroplasticity biomarkers. That makes Semax more defensible…
Filip 2007 supports direction more than certainty. The existing rationale points to this narrower claim: JmjC histone-demethylase cofactor biology is neuroplasticity-adjacent, and this verified source adds preclinical support. Human data are absent.…
Soh 2024 anchors the most relevant signal. Glycine fits neuroplasticity because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because many…
Whole-Body Vibration may promote proprioceptive re-patterning and sensory input that support rehabilitation learning, especially in neurological populations. Current research shows functional improvements in motor tasks, but biomarkers of synaptic change remain unmeasured.…
The umbrella review by Poon et al. 2024 found that high-intensity interval protocols raise circulating BDNF, a factor linked to neuroplasticity, in about half of the examined studies. HIIT-based sessions can open…
The evidence points to a plausible use case without proving a universal response. Zhang et al. 2025 is the best anchor here because it reports 25 randomized trials, 1486 participants and improved…
The evidence does not support Metformin as a neuroplasticity enhancer, and no human studies have measured brain-training outcomes (see the null findings in the exercise-focused trial by Konopka 2019). Metformin's interaction with…
Semaglutide has plausible GLP-1 brain mechanisms but no conclusive human neuroplasticity endpoint in this report. Yao 2024 supports metabolic effects, which may create a better environment for the brain in high-risk users.…
McCoy 2013 anchors the most relevant signal. Dihexa fits neuroplasticity only as a research-chemical hypothesis around synaptogenesis and memory circuits, not as a proven human nootropic. The score stays bounded because the…
Mechanistic mTOR and autophagy links are plausible, but human neurological effects were not significant in the systematic review.
RF training may enhance prefrontal-autonomic coupling; thin direct human data.
No direct neuroplasticity endpoint was verified. EAAs support tissue protein synthesis generally but are not a targeted BDNF, learning, or synaptic-plasticity intervention.
Mechanistic support is reasonable. Hippocampal D1/D5-dependent LTP transformation (Mikhaylova/Behnisch 2007) and BDNF + NGF mRNA induction in striatum, hypothalamus, and hippocampus (Salimgareeva 2012) point to a plasticity-supporting profile. No human imaging or…
The NGF and BDNF finding in rat hippocampus is the strongest mechanistic case noopept has, but no human plasticity endpoint has been measured.
Intense intervals can raise circulating BDNF and open short plasticity windows, but translation to durable learning gains is unproven for sprint protocols and varies widely between people.
Neuroplasticity remains exploratory. GHK-related neuroprotection and VEGFA pathway signals exist in animal work, including Zhang 2018, but no human neuroplasticity endpoint trial exists for GHK-Cu.
PS supports PKC-mediated membrane signaling and synaptic function, with clinical support only indirectly through memory trials. This is relevant but not a direct neuroplasticity endpoint.
Neuroplasticity is mostly preclinical and cognition-adjacent. Withanolide biology supports neuronal-growth hypotheses, and Zhu 2026 improves the adult cognition evidence base. Direct human brain-imaging or structural neuroplasticity trials remain absent.
No human tirzepatide neuroplasticity endpoint is verified. Incretin pathways have neurobiological plausibility. Obesity and diabetes trials do not prove neuroplasticity enhancement. Keep below neutral and resist mechanistic over claims (Drucker 2018).
J-147 raised hippocampal BDNF and NGF in nearly every study, a plausible plasticity mechanism. This is a molecular readout in animals, not a measured human plasticity outcome.
IGF-1 supports synaptic plasticity and brain repair pathways, and Baker 2012 gives a human cognition signal. Direct tesamorelin neuroplasticity biomarkers remain sparse.
Autophagy supports neural maintenance, but verified human neuroplasticity evidence is not clean.
Preclinical neurotrophic-pathway data and BBB penetration are interesting, but human neuroplasticity endpoints are limited.
Animal neurogenesis pathways exist, but human neuroplasticity endpoints are not established. Keep this exploratory and do not treat thymosin alpha-1 as a cognitive-enhancement peptide.
BDNF data support a neuroplasticity hypothesis. Inozemtseva 2008 reported hippocampal BDNF-expression effects after intranasal Selank in rats, but no human neuroplasticity endpoint exists.
DHA supports neuronal membrane structure, but clinical neuroplasticity outcomes remain limited and not practice-changing.
Androgens influence brain biology, but human neuroplasticity outcomes from TRT are not established. The null T Trials cognition result keeps the score low despite mechanistic interest.
Glutamate modulation is mechanistically relevant, but human neuroplasticity endpoints are absent. Stays preclinical.
Preclinical BDNF-related evidence exists, but human neuroplasticity evidence is thin.
Nerve growth factor interactions; limited direct evidence. Preclinical nerve repair does not establish broad cognitive or skill-learning plasticity.
Novel motor patterns and involuntary recruitment may challenge cortical control, especially in rehab. Direct neuroplasticity endpoints are sparse, so WB-EMS should be framed as motor re-education support, not a brain-training technology.
No direct human neuroplasticity evidence was identified. Tongkat Ali should not be framed as a brain-rewiring or learning-enhancement supplement.
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 9 of 36 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Neurofeedback | Not priced yet | ||
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Saffron | Not priced yet | ||
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Dihexa | $30–$60 | 8-12 mg/day sublingual | Research use only |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Essential Amino Acids | Not priced yet | ||
| Bromantane (Ladasten) | $12–$30 | 30 mg | Grey market |
| Noopept (Omberacetam) | $5–$27 | 20 mg | Grey market |
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Phosphatidylserine | $20–$50 | 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food | Over the counter |
| Ashwagandha | $15–$30 | 300 mg KSM-66 with breakfast and 300 mg with dinner | Over the counter |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| J-147 | Not priced yet | ||
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Astaxanthin | Not priced yet | ||
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Selank | $30–$60 | 0.15% intranasal spray, roughly 1-3 sprays per nostril per day depending on actuation size | Grey market |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| NAC (N-Acetylcysteine) | $5–$15 | 600 to 1,200 mg/day | Over the counter |
| L-Theanine | $3–$8 | 200 mg L-theanine + 100 mg caffeine | Over the counter |
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Full-Body EMS | Not priced yet | ||
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
Ranked by the live Focus and cognition subrating, not the overall score. Methylene blue leads at 6.5–7.0/10 despite a lower overall, 6.0–6.5/10. Bromantane climbs from ninth to fourth.…
Semax scores 7.1/10 against noopept's 6.2/10 and wins five of the eight use cases both reports score. Noopept is oral, cheaper at $5 to $27 a month, and…
Bromantane, for anything you plan to repeat. It scores 7.0–7.5/10 against phenylpiracetam's 5.5–6.0/10 and wins every shared use case that is not a floor tie: energy 6.2/10 to…
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.5–5.0/10 and dihexa 4.0–4.5/10, and the gap is entirely safety: dihexa potentiates the…
Epitalon, if sleep is the question. It scores sleep quality 6.5–7.0/10 against pinealon's 1.5–2.0/10, because it acts on the pineal gland and melatonin output while pinealon is a…
Semax scores 7.0–7.5/10 and cerebrolysin 6.0–6.5/10. Semax wins cognition, neuroplasticity and nerve regeneration, costs an estimated $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.0–7.5/10 against dihexa's 4.0–4.5/10, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
Neurofeedback, at 8.0–8.5 out of 10 for neuroplasticity. Ostinelli et al.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5–6.0 out of 10 for neuroplasticity.
Dihexa scores 5.0–5.5 out of 10 for neuroplasticity but only 4.0–4.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
36 of the 90 interventions evaluated for neuroplasticity score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
